Jonas Rieth

University of Tübingen | Immunology and Oncology

[Peptide-based Immunotherapy @LabWalz]

We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19 #vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found:

[Peptide-based Immunotherapy @LabWalz]

Very proud that @JulianeWalz received this years best abstract award at the @dgho_eV for her presentation on our peptide-based #COVID19 #vaccine for patients affected by antibody shortage

[Peptide-based Immunotherapy @LabWalz]

Two exciting talks were held by our lab members @mroerden1 and Jens Bauer on #Covid_19 #tcell responses in #Cancer patients and a new fusion protein as potential immunotherapeutic target for the treatment of FLHCC at this years @dgho_eV meeting

[Peptide-based Immunotherapy @LabWalz]

Check out our latest preprint: This first comprehensive analysis of #SARS_CoV_2 immune responses in #cancer patients reports on the implications of impaired SARS-CoV-2 T cell responses for understanding pathophysiology and predicting severity of #COVID19 https://t.co/D0e35nKGjr

[Tagblatt Redaktion @Tagblatt]

Der Wissenschaftler der Uni Tübingen wird mit dem Landesforschungspreis 2020 ausgezeichnet, der mit 100.000 Euro dotiert ist. https://t.co/X9vlEvLWtg

[Peptide-based Immunotherapy @LabWalz]

Check out the article from the local newspaper @Tagblatt
https://t.co/QX4w45A4hZ

[Peptide-based Immunotherapy @LabWalz]

We are starting a phase-I #clinicaltrial for our peptide #vaccine against chronic lymphocytic leukemia (CLL). The aim is to avoid relapse due to minimal residual disease after first line therapy with Ibrutinib. @uktuebingen

https://t.co/rzsXlUD2HT

[Uniklinikum Tübingen @uktuebingen]

Können frühere Erkältungen gegen #Covid_19 schützen?🤔Das Forscherteam um Dr. @JulianeWalz zeigt, wie das #Immunsystem aus bereits überstandenen Infektionen lernt und sich anpasst.
#uniklinikumtuebingen #Coronavirus #TZellen #
@LabWalz

[Peptide-based Immunotherapy @LabWalz]

Check out this short german TV coverage on our #SARS_CoV_2 peptide #vaccine by @3sat

https://t.co/6I2rZgwzsY

[Peptide-based Immunotherapy @LabWalz]

Very happy and excited that one of our publications is among the 5 most popular scientific papers in the Nature Index journals #sciencetwitter #SARS_CoV_2

[Peptide-based Immunotherapy @LabWalz]

Check out our latest review "The peptide #vaccine of the future" by @AnnikaNel published in @molcellprot

https://t.co/Zy86fM8Xh0
https://t.co/VwwqifJe9V

[Peptide-based Immunotherapy @LabWalz]

Check out the online preprint on our work defining #SARSCoV2 T-cell epitopes

SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition https://t.co/nvMFRyyIah